Lonza expands PyroCell pyrogen testing portfolio with two new rapid systems

Published: 25-Oct-2023
Cleaning Analysis Pharmaceutical

Lonza has launched PyroCell MAT Rapid System and PyroCellMAT Human Serum (HS) Rapid System, two sustainable monocyte activation test (MAT) systems containing the new PeliKine Human IL-6 Rapid ELISA Kit

Lonza has launched two new rapid monocyte activation test (MAT) systems, the PyroCell (registered trademark) MAT Rapid System and PyroCell MAT Human Serum (HS) Rapid System, to streamline and simplify rabbit-free pyrogen testing.

The systems, which will replace Lonza’s current MAT system kit offerings, contain the new PeliKine Human IL-6 Rapid ELISA Kit that minimises hands-on time and reduces time-to-results from two days to two hours. The new tests give pharma manufacturers easier, faster, and more efficient MAT testing options for product safety testing while helping to reduce the reliance on animals.

We’ve leveraged our long collaboration with Essange Reagents, formerly Sanquin Reagents, to deliver the new PyroCell MAT Rapid Systems, offering customers two MAT solutions that are easier to execute. Transitioning to rabbit-free, sustainable pyrogen testing has never been simpler

- Orla Cloak, VP, Head of Bioprocessing Solutions

Historically, pyrogen testing of pharmaceuticals has relied on the Rabbit Pyrogen Test (RPT), an unsustainable method requiring significant time-to-results. Pharma manufacturers now face growing pressure to discontinue the RPT due to ethical concerns, regulatory initiatives, and directives to increase the efficiency of QC pyrogen testing programmes.

Lonza expands PyroCell pyrogen testing portfolio with two new rapid systems

Lonza’s PyroCell MAT Rapid Systems, with the new PeliKine Human IL-6 Rapid ELISA Kit, help streamline QC testing workflows. The new ELISA kit contains pre-coated plates and an improved protocol with combined incubation steps, minimising hands-on time and reducing time-to-results to just two hours. The new rapid ELISA kit results are comparable to the current industry standard, making switching to the new test simple for customers. Most critically, the new rapid ELISA kit has been specifically validated for use with the MAT.

Orla Cloak, VP, Head of Bioprocessing Solutions, Lonza, said: “With the RPT set to be discontinued in Europe by 2026, and sustainability a growing focus, pharmaceutical manufacturers are looking to adopt an RPT replacement. We’ve leveraged our long collaboration with Essange Reagents, formerly Sanquin Reagents, to deliver the new PyroCell MAT Rapid Systems, offering customers two MAT solutions that are easier to execute. Transitioning to rabbit-free, sustainable pyrogen testing has never been simpler.”

Lonza will discontinue its current PyroCell MAT System and PyroCell MAT Human Serum (HS) System by early 2024.

  • Companies:
  • Lonza
See more

You may also like

Regulatory

UPDATE: US Pharmacopeia makes comments public on endotoxin testing overhaul

Read more
The USP has published the comments the organisation received in response to the addition of non-animal derived endotoxin testing methods, as well as an FAQ page on the issue

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    What is ISO 8 cleanroom classification? Each cleanroom class is denoted by a maximum concentration of particles per cubic meter or cubic foot of air. ISO 8 is the second lowest cleanroom classification
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Integrity testing of HEPA filters: A practical approach Filtering the air in aseptic process areas is critical to maintaining the cleanliness of the production environment. Jesus Casas provides tips to ensure HEPA filters are fit for purpose once installed in your facility
  3. The three musketeers of pharmaceutical quality control GMP, GAMP5, and 21CFR11 explained
  4. APIs: Bioreactor hoists with a multipurpose twist Peter Devenny of PalPharma describes the solution for a biotech facility in Switzerland designed to handle filled bioreactors across GMP areas to produce ten metric tons of antibody per year
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Battling biofilms in cleanrooms Michelle Locke from Teknomek discusses how it is possible to combat the persistent threat of biofilms with the right cleanroom furniture, equipment, and cleaning protocols

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

UPDATE: US Pharmacopeia makes comments public on endotoxin testing overhaul

The USP has published the comments the organisation received in response to the addition of non-animal derived endotoxin testing methods, as well as an FAQ page on the issue
Analysis

Lonza to phase out traditional endotoxin testing LAL and TAL assay reader for new tech

The company has launched the Nebula Absorbance Reader that is a technologically advanced, high-performance replacement reader, which delivers results comparable to those typically found with the traditional method and will facilitate the smooth continuation of current pyrogen and endotoxin testing programmes
Pharmaceutical

Q&A: Lonza’s PyroCell Monocyte activation test

Lonza has launched the PyroCell MAT that uses human serum instead of foetal bovine serum for pharmaceutical testing, but how does it change the status quo?
Design & Build

Lonza commissions BAM for Chemelot mRNA facility renovation

Lonza has commissioned BAM to renovate the ground floor up to and including the second floor of its Brighthouse building 300 on the Brightlands Chemelot Campus
Cleaning

Q&A on Lonza’s new PyroCell Monocyte Activation Test

Speaking to Katrin Pauls from Lonza about the launch of the company's PyroCell MAT, which uses human serum instead of foetal bovine serum for pharmaceutical testing, and how it changes the status quo
Cleaning

Lonza debuts first multimode reader to streamline quantitative endotoxin detection

The global science company has launched the Nebula Multimode Reader, the first multimode reader qualified for use with Lonza’s turbidimetric, chromogenic and recombinant endotoxin detection methods
Regulatory

Lonza launches non-bovine test for non-endotoxin pyrogen contaminants

Lonza has launched the PyroCell Monocyte Activation Test that uses human serum instead of fetal bovine serum for pharmaceutical testing
Subscribe now